Dr. Chen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
Bethesda, MD 20892Phone+1 301-496-1196
Education & Training
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1989 - 1991
- University of Texas Southwestern Medical Center/St Paul Medical CenterResidency, Internal Medicine, 1987 - 1989
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1986 - 1987
- University of Tennessee Health Science Center College of MedicineClass of 1986
Certifications & Licensure
- FL State Medical License 1997 - 2026
- TX State Medical License 1988 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1409 citationsiRECIST: guidelines for response criteria for use in trials testing immunotherapeuticsLesley Seymour, Jan Bogaerts, Andrea Marie Perrone, Robert Ford, Lawrence H. Schwartz
The Lancet. Oncology. 2017-03-01 - 2 citationsTrastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.Roisin M Connolly, Victoria Wang, David M Hyman, Petros Grivas, Edith P Mitchell
Clinical Cancer Research. 2024-04-01 - 27 citationsThe NCI-MATCH trial: lessons for precision oncology.Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, Alice P Chen, Shuli Li
Nature Medicine. 2023-06-01
Journal Articles
- Effect of Capivasertib in Patients with an AKT1 E17K-Mutated TumorKevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology
Authored Content
- Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
- Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
- Phase II Trial of Veliparib in Patients with Previously Treated BRCA-Mutated Pancreas Ductal Adenocarcinoma☆January 2018
Press Mentions
- Drug Approved to Help Young Patients Battle a Rare CancerJanuary 2nd, 2023
- Slips, Slides: Winter Injuries Can Be SeriousJanuary 2nd, 2023
- NIH Clinical Trials Apply Genomics to Chronic Disease ManagementJune 6th, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: